TY - JOUR T1 - Predicting elimination of evolving virus variants JF - medRxiv DO - 10.1101/2021.06.24.21259501 SP - 2021.06.24.21259501 AU - Elliott Hughes AU - Rachelle Binny AU - Shaun Hendy AU - Alex James Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/25/2021.06.24.21259501.abstract N2 - As the SARS-CoV-2 virus spreads around the world new variants are appearing regularly. Although some countries have achieved very swift and successful vaccination campaigns, on a global scale the vast majority of the population is unvaccinated and new variants are proving more resistant to the current set of vaccines. We present a simple model of disease spread which includes the evolution of new variants and varying vaccine effectiveness to these new strains. We show that rapid vaccine updates to target new strains are more effective than slow updates and containing spread through non-pharmaceutical interventions is vital whilst these vaccines are delivered. Finally when measuring the key model inputs, e.g. the rate at which new mutations and variants of concern emerge, is difficult we show how an observable model output, the number of new variants which have been seen, is strongly correlated with the probability the virus is eliminated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the New Zealand Ministry of Business, Innovation and Employment and Te Pūnaha Matatini, Centre of Research Excellence in Complex Systems.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study uses existing published data and no ethical approval was needed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data was previously published https://data.worldbank.org https://ourworldindata.org/covid-vaccinations https://covid19dashboard.regeneron.com https://github.com/YouGov-Data/covid-19-tracker https://www.ipsos.com/sites/default/files/ct/news/documents/2021-03/global-attitudes-on-a-covid-19-vaccine-march-2021- ER -